MARKET

CCXI

CCXI

ChemoCentryx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

39.75
+1.17
+3.03%
Closed 17:27 04/02 EDT
OPEN
38.39
PREV CLOSE
38.58
HIGH
40.22
LOW
37.42
VOLUME
519.42K
TURNOVER
--
52 WEEK HIGH
51.36
52 WEEK LOW
6.16
MARKET CAP
2.45B
P/E (TTM)
-40.8320
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CCXI stock price target is 60.50 with a high estimate of 64.00 and a low estimate of 54.00.

EPS

CCXI News

More
  • Cramer's lightning round: 'I think it is the time to buy Domino's'
  • CNBC.com · 12h ago
  • Edited Transcript of CCXI earnings conference call or presentation 10-Mar-20 9:00pm GMT
  • Thomson Reuters StreetEvents · 1d ago
  • Cramer's lightning round: Procter & Gamble has 'unbelievable numbers'
  • CNBC.com · 1d ago
  • Cramer's lightning round: Peloton is the 'ultimate stay-at-home stock'
  • CNBC.com · 2d ago

Industry

Pharmaceuticals
+2.64%
Pharmaceuticals & Medical Research
+2.80%

Hot Stocks

Symbol
Price
%Change

About CCXI

ChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. Its late stage compounds include Avacopan (CCX168) and CCX140. Avacopan (CCX168) is an orally administered complement inhibitor targeting the C5a receptor (C5aR), and is being developed for orphan and rare diseases, including anti-neutrophil cytoplasmic auto-antibody associated vasculitis (AAV); atypical hemolytic uremic syndrome (aHUS), and complement 3 glomerulopathy (C3G). CCX140 is an orally administered inhibitor of the chemokine receptor known as C-C chemokine receptor type 2 (CCR2), in development for diabetic nephropathy (DN), a form of chronic kidney disease (CKD), and for focal segmental glomerulosclerosis (FSGS).
More

Webull offers kinds of ChemoCentryx Inc stock information, including NASDAQ:CCXI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CCXI stock news, and many more online research tools to help you make informed decisions.